Scott Francy, MD

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.